Obesity Medicine

Your daily dose of the clinical news you may have missed.

Adolescents with overweight or obesity and baseline HbA1c 6.3%-6.4% were at 72-fold greater risk for T2D than those with HbA1c of 5.5%, a new cohort study finds.

The GLP-1 RAs Wegovy, Ozempic, Mounjaro, and Zepbound have taken up more real estate on the US map in some areas than others. Click to find out more.

When it comes overweight, obesity, and prescription drugs for weight loss, these results from the National Poll on Healthy Aging suggest older US adults need guidance.

Your daily dose of the clinical news you may have missed.

Findings from new study suggest that promoting healthy coping strategies for stress during early life can reduce cardiometabolic risk, report researchers.

Each additional month of breastfeeding beyond 3 months correlated with a significantly lower child BMIz, especially for mothers identified as overweight or obese.

Your daily dose of the clinical news you may have missed.

Compared to the lowest intake of AS-rich food and beverages, the highest intake was associated with a 59% higher risk of developing MetS, according to new findings.

While the FDA's preliminary evaluation has not surfaced evidence of a link, the agency says it "cannot definitively rule out that a small risk may exist," and so will continue research.

Your daily dose of the clinical news you may have missed.

Semaglutide was associated with a lower risk of first-time and recurrent suicidal ideations in patients with obesity or overweight or T2D, according to new study.

Angela Fitch, MD, president of the Obesity Medicine Association, details what to look forward to this year in terms of obesity management.

Individuals with "lean NAFLD" may be at similar risk of NASH, cirrhosis, nonliver cancer, and death as as those with NAFLD and overweight or obesity, authors say.

President of the Obesity Medicine Association discusses how clinician perspectives on obesity and obesity treatment are changing for the better.

In an open letter to the public, Lilly decries use of tirzepatide products Mounjaro and Zepbound for nonmedical purposes and warns of counterfeit formulations.

Findings underscore the importance of preventive measures and management of risk factors associated with CKD in adolescents with elevated BMI, report researchers.

Your daily dose of the clinical news you may have missed.

Angela Fitch, MD, president of the Obesity Medicine Association discusses key pharmaceutical and research developments in obesity medicine in 2023.

Your daily dose of the clinical news you may have missed.

The American Board of Obesity Medicine says annual first-time certificates now exceed those for cardiology, pulmonology, and medical oncology.

The task force recommends clinicians provide or refer children and adolescents with a high BMI to intensive, comprehensive behavioral interventions.

Study participants randomized to placebo for 1 year after 36 weeks on tirzepatide had mean weight regain of 14% vs augmented loss among those who continued on the medication.

While incretin-based antiobesity medications are the optimal treatment for some, there are other less costly approaches that can support weight loss success, this author says.

The dual GIP/GLP-1 mimetic is available by prescription for adults with obesity or overweight with comorbidities and Lilly is offering a savings card program.